These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 20082649)
1. Anticoagulation for atrial fibrillation patients with CHADS score of 1. Lane DA; Lip GY J Cardiovasc Electrophysiol; 2010 May; 21(5):508-10. PubMed ID: 20082649 [No Abstract] [Full Text] [Related]
2. The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1. Lee BH; Park JS; Park JH; Park JS; Kwak JJ; Hwang ES; Kim SK; Choi DH; Kim YH; Pak HN J Cardiovasc Electrophysiol; 2010 May; 21(5):501-7. PubMed ID: 20021521 [TBL] [Abstract][Full Text] [Related]
3. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study. Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184 [TBL] [Abstract][Full Text] [Related]
4. [Anticoagulation in atrial fibrillation. Strategies in special situations]. Volkmann H; Walter M; Walter C; Vetter S Clin Res Cardiol Suppl; 2011 May; 6():58-65. PubMed ID: 22528179 [TBL] [Abstract][Full Text] [Related]
5. [Antithrombotic treatment in atrial fibrillation. Background to new recommendations and therapeutic alternative]. Själander A; Wallentin L; Rosenqvist M; Svensson P Lakartidningen; 2008 Sep 10-16; 105(37):2478-80. PubMed ID: 19006862 [No Abstract] [Full Text] [Related]
6. Anticoagulation of atrial fibrillation in older people: a clinical practice observational study. Abdelhafiz AH; Wheeldon NM J Am Geriatr Soc; 2006 Jan; 54(1):176-7. PubMed ID: 16420226 [No Abstract] [Full Text] [Related]
8. [Antithrombotic therapy in patients with atrial fibrillation: a comment on the European guidelines]. Said SM; Nahrendorf W; Schmidt H; Braun-Dullaeus RC Dtsch Med Wochenschr; 2011 Jun; 136(25-26):1384-5. PubMed ID: 21674428 [No Abstract] [Full Text] [Related]
9. New concepts and approaches to stroke prevention in the new European Society of Cardiology guidelines for the management of atrial fibrillation. Kuzniatsova N; Lip GY Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1643-7. PubMed ID: 21108546 [No Abstract] [Full Text] [Related]
10. [Guidelines for antithrombotic therapy in atrial fibrillation: what the Italian Hemostasis and Thrombosis Society thinks]. Prisco D Haematologica; 2001 Sep; 86(9 Suppl):12-3. PubMed ID: 11759618 [No Abstract] [Full Text] [Related]
11. Thromboembolic events occur despite sinus rhythm maintenance in patients treated for atrial fibrillation: The Canadian Trial of Atrial Fibrillation experience. Thibault B; Talajic M; Dubuc M; Guerra P; Gagné P; Roy D; Connolly S; Can J Cardiol; 2004 Feb; 20(2):195-9. PubMed ID: 15010743 [TBL] [Abstract][Full Text] [Related]
12. Pro: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation. Mant JW Thromb Haemost; 2008 Jul; 100(1):14-5. PubMed ID: 18612531 [No Abstract] [Full Text] [Related]
13. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Nieuwlaat R; Olsson SB; Lip GY; Camm AJ; Breithardt G; Capucci A; Meeder JG; Prins MH; Lévy S; Crijns HJ; Am Heart J; 2007 Jun; 153(6):1006-12. PubMed ID: 17540203 [TBL] [Abstract][Full Text] [Related]
14. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation. Hylek EM Thromb Haemost; 2008 Jul; 100(1):16-7. PubMed ID: 18612532 [No Abstract] [Full Text] [Related]
16. [HAS-BLED shows bleeding risk in ischemic stroke and atrial fibrillation. But adjustments are needed for safer assessment, according to quality study]. Alshakarchi J; Terént A Lakartidningen; 2012 Sep 19-26; 109(38):1670-2. PubMed ID: 23094397 [No Abstract] [Full Text] [Related]
17. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Lopes RD; Alexander JH; Al-Khatib SM; Ansell J; Diaz R; Easton JD; Gersh BJ; Granger CB; Hanna M; Horowitz J; Hylek EM; McMurray JJ; Verheugt FW; Wallentin L; Am Heart J; 2010 Mar; 159(3):331-9. PubMed ID: 20211292 [TBL] [Abstract][Full Text] [Related]
18. [Complicated priorities regarding antithrombotic treatment of atrial fibrillation. Difficult to understand priority list in the national guidelines--new studies can make them clearer]. Mooe T Lakartidningen; 2008 Sep 10-16; 105(37):2472-3. PubMed ID: 19006861 [No Abstract] [Full Text] [Related]
19. Stroke prevention in atrial fibrillation patients. Marinigh R; Lip GY; Lane DA Expert Opin Pharmacother; 2010 Oct; 11(14):2331-50. PubMed ID: 20718589 [TBL] [Abstract][Full Text] [Related]
20. Is computer-assisted, long-term warfarin therapy safe and efficacious for patients with nonrheumatic atrial fibrillation? Perez-Gomez F Nat Clin Pract Cardiovasc Med; 2005 Feb; 2(2):82-3. PubMed ID: 16265377 [No Abstract] [Full Text] [Related] [Next] [New Search]